Amyotrophic lateral sclerosis (ALS) is a neurodegenerative illness that affects nerve cells in the brain and spinal cord that regulate voluntary muscles. It is also referred as Lou Gehrig’s disease and motor neuron disease (MND). The disease is progressive, which means that it will get worse over time. According to a study issued in the Centers for Disease Control and Prevention (CDC), 14,713 people were diagnosed with ALS in the U.S. in 2016, with a recurrence incidence of 4.7 cases per 100,000 in 2012. According to the same study, the prevalence rate jumped to 5.0 cases per 100,000 persons in 2013, with 15,908 people diagnosed with ALS. As the prevalence of ALS rises, the global amyotrophic lateral sclerosis (ALS) treatment market is likely to expand in the near future.
Get PDF Brochure with COVID19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/1206
The global amyotrophic lateral sclerosis treatment market is expected to grow as more innovative drugs are approved.
Radicava (edaravone), a new drug used to treat amyotrophic lateral sclerosis, was approved by the U.S. Food and Drug Administration (FDA) in May 2017. Around two decades later, this was the first medicine to be approved by the U.S. Food and Drug Administration (FDA) for ALS. The approval of this medicine would provide individuals who are suffering from this terrible condition another option. As the incidence of ALS rises, the adoption rate of this drug is expected to grow, driving market growth. In 2015, the drug received approval in South Korea and Japan.
During the forecast period (2017-2025), several associations’ initiatives to raise public awareness regarding the diagnosis and treatment of ALS are expected to fuel market growth. For instance, in 2014, the ALS Ice Bucket Challenge, a social media–based campaign, attracted widespread public attention and raised ALS awareness. The Ice Bucket Challenge was reintroduced in 2015 by a group of ALS groups in the U.S., including the ALS Therapy Development Institute, ALS Association, and, Les Turner ALS Foundation, to generate funds and promote awareness of ALS among the general public.
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Taxonomy
The global amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type and distribution channel.
On the basis of drug type, the global amyotrophic lateral sclerosis treatment market is segmented into:
-
Riluzole
-
Edaravone (Radicava)
On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into:
-
Hospital Pharmacies
-
Retail & Online Pharmacies
North America is expected to account for largest share in the global amyotrophic lateral sclerosis market, with manufacturers focusing more on innovative drug development for ALS.
As major companies in the region are focusing on collaborations for product development, North America is expected to hold a dominant position in the global amyotrophic lateral sclerosis treatment market. For instance, Pfizer Inc. and Sangamo Therapeutics, Inc., collaborated in January 2018 to develop a potential gene therapy for the treatment of ALS using zinc finger protein transcription factors (ZFP-TFs). Companies in Asia Pacific’s emerging economies are focusing on creating new drugs to treat ALS. For instance, major pharmaceutical companies such as Takeda Pharmaceutical Company Ltd and Mitsubishi Tanabe Pharma Corporation are developing ALS drugs.
Major market players are collaborating with a variety of research institutes and companies to develop a drug for the treatment of amyotrophic lateral sclerosis.
Mitsubishi Tanabe Pharma Corporation, Trans Chromosomics Inc., and Order Made Medical Research Corporation, completed a strategic collaboration in December 2017 to develop an antibody drug to treat neurodegenerative diseases like ALS. In the same month, the Montreal Neurological Institute teamed up with Takeda Pharmaceutical Company Ltd. to develop new ALS drugs. Celgene Corporation and Evotec formed a strategic drug discovery partnership in 2016 to develop new drugs for neurodegenerative diseases such as ALS.
Johnson & Johnson and Janssen Research & Development, a division of Janssen Pharmaceutica NV collaborated in 2013 with three prominent Belgian academic institutions and research facilities to develop new treatment drugs for neurodegenerative diseases such as ALS.
Major Players Are: Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/1206
Reasons to Purchase this Report
• Current and future of global Amyotrophic Lateral Sclerosis (ALS) Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837